Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 15.26 is 124% above its 5-year average of 6.80, near the high end of its 5-year range (2.09–20.86).
As of the fiscal period ended Tuesday, June 30, 2026. 17.14% above its 12-month average of 13.02.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 15.26.
QUICK RATIO (ACID-TEST)
15.26
QUICK RATIO (ACID-TEST) AVG TTM
13.02
QUICK RATIO (ACID-TEST) AVG 3Y
9.15
QUICK RATIO (ACID-TEST) AVG 5Y
6.80
QUICK RATIO (ACID-TEST) AVG 10Y
7.84
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.14%
CURRENT VS 3Y AVG
+66.78%
CURRENT VS 5Y AVG
+124.35%
CURRENT VS 10Y AVG
+94.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.32
median of 859 covered companies
CURRENT VS SECTOR MEDIAN
+359.54%
vs the sector median at left
Yarrow Bioscience Inc
Market Cap
$179.39M
Quick Ratio (Acid-Test)
15.26
TTM Avg
13.02
3Y Avg
9.15
5Y Avg
6.80
Market Cap
$181.30M
Quick Ratio (Acid-Test)
4.98
TTM Avg
16.09
3Y Avg
15.64
5Y Avg
15.37
Market Cap
$175.93M
Quick Ratio (Acid-Test)
11.22
TTM Avg
14.99
3Y Avg
15.44
5Y Avg
13.43
Market Cap
$182.93M
Quick Ratio (Acid-Test)
14.32
TTM Avg
7.65
3Y Avg
9.22
5Y Avg
9.58
Market Cap
$183.65M
Quick Ratio (Acid-Test)
15.70
TTM Avg
3.42
3Y Avg
4.67
5Y Avg
3.16
Market Cap
$173.76M
Quick Ratio (Acid-Test)
3.49
TTM Avg
3.52
3Y Avg
4.49
5Y Avg
5.44
Market Cap
$172.61M
Quick Ratio (Acid-Test)
1.41
TTM Avg
1.25
3Y Avg
1.14
5Y Avg
1.20
Market Cap
$172.51M
Quick Ratio (Acid-Test)
12.82
TTM Avg
9.83
3Y Avg
6.43
5Y Avg
5.45
Market Cap
$171.69M
Quick Ratio (Acid-Test)
1.25
TTM Avg
2.29
3Y Avg
3.57
5Y Avg
4.16
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $179.39M | 15.26 | 13.02 | 9.15 | 6.80 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.30M | 4.98 | 16.09 | 15.64 | 15.37 |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.93M | 11.22 | 14.99 | 15.44 | 13.43 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.93M | 14.32 | 7.65 | 9.22 | 9.58 |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.65M | 15.70 | 3.42 | 4.67 | 3.16 |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | 3.49 | 3.52 | 4.49 | 5.44 |
| Journey Medical Corporation (DERM)vs › | $172.61M | 1.41 | 1.25 | 1.14 | 1.20 |
| Precision BioSciences, Inc. (DTIL)vs › | $172.51M | 12.82 | 9.83 | 6.43 | 5.45 |
| Cue Biopharma, Inc. (CUE)vs › | $171.69M | 1.25 | 2.29 | 3.57 | 4.16 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.04M | 7.90 | 9.91 | 10.86 | 18.34 |
Quick Ratio
15.26
Excludes inventory
Current Ratio
15.26
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 15.26 |
| 2026-03-31 | 20.86 |
| 2025-12-31 | 12.53 |
| 2025-09-30 | 8.87 |
| 2025-06-30 | 7.60 |
| 2025-03-31 | 4.47 |
| 2024-12-31 | 4.35 |
| 2024-09-30 | 5.81 |
| 2024-06-30 | 7.13 |
| 2024-03-31 | 13.02 |
| 2023-12-31 | 12.73 |
| 2023-09-30 | 2.71 |
| 2023-06-30 | 3.59 |
| 2023-03-31 | 4.39 |
| 2022-12-31 | 4.10 |
| 2022-09-30 | 6.44 |
| 2022-06-30 | 7.60 |
| 2022-03-31 | 7.06 |
| 2021-12-31 | 3.04 |
| 2021-09-30 | 3.24 |
| 2021-06-30 | 2.09 |
| 2021-03-31 | 6.27 |
| 2020-12-31 | 3.67 |
| 2020-09-30 | 3.95 |
| 2020-06-30 | 4.68 |
| 2020-03-31 | 1.68 |
| 2019-12-31 | 7.35 |
| 2019-09-30 | 9.88 |
| 2019-06-30 | 9.50 |
| 2019-03-31 | 11.78 |
| 2018-12-31 | 14.62 |
| 2018-09-30 | 19.16 |
| 2018-06-30 | 18.06 |
| 2018-03-31 | 18.85 |
| 2017-12-31 | 8.55 |
| 2017-09-30 | 10.49 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 8.08 |
| 2016-09-30 | 0.00 |
